All the Right Technology in All the Right Places:

The Necessary Evolution of Urine Drug Testing

Frederick G. Strathmann, PhD, DABCC (CC, TC)

ARUP Laboratories Medical Director of Toxicology Director of High Complexity Platforms – Mass Spectrometry Scientific Director of BioComputing Assistant Director – ARUP Institute for Clinical & Experimental Pathology University of Utah Assistant Professor of Pathology

AACC Annual Meeting (August 2nd, 2016)






Current State of Urine Toxicology Testing

- Immunoassay screen only
- Immunoassay screen with reflex to confirmation by LC/GC MS
- Direct to GC/LC-MS
- Hybrid (IA + LC-MS without "confirmation")
- Immunoassays
- Quadrupole
- Time-of-Flight
- Quadrupole + Time-of-Flight





Tried and True Workflow








Challenges with (some) IA Screens

- Presumptive screening method used
 - e.g., immunoassay for opiates







More Problems with Immunoassays

	Immunoassay screens			Confirmation (tested when screen POS)				Confirmed POS Specimens			
	Total tested (#)	Pos (#)	Pos (%)	Confirm pos (#)	Confirm neg (#)	True pos (%)	<mark>False pos</mark> (%)	Males (#)	Females (#)	Males (%)	Females (%)
AMPH ^a	8,825	705	8.0	608	97	86.2	13.8	263	345	43.3	56.7
BARB	8,825	163	1.9	159	4	97.5	2.5	54	105	34.0	66.0
BENZO	8,825	1,130	12.8	1,125	5	99.6	0.4	480 ^b	653 ^b	42.4	57.6
COC	8,825	237	2.7	237	0	100.0	0.0	140	97	59.1	40.9
ETOH	2,296	35	1.5	35	0	100.0	0.0	16	19	45.7	54.3
MDMA ^a	8,825	174	2.0	0	174	0.0	100	0	0	_	_
MTD	8,825	262	3.0	262	0	100.0	0.0	98	164	37.4	62.6
OPI ^c	8,825	2,642	29.9	1,744	898	66.0	34.0	820	924	47.0	53.0
OXY ^c	8,825	1,215	13.8	1,192	23	98.1	1.9	601 ^c	684 ^c	46.8	53.2
PCP	8,825	4	0.05	0	4	0.0	100	0	0	-	_
PPXY	8,825	4	0.05	3	1	75.0	25.0	2	1	66.7	33.3
THC	8,825	1,793	20.3	1,777	16	99.1	0.9	906	871	51.0	49.0
Totals	99,371	8,364	8.4%	7,142	1,222	85.4%	14.6%	3,380	3,863		

Table IV. Summary Results from Immunoassay Screens and Confirmatory Testing

Johnson-Davis et al. (2016). Journal of Analytical Toxicology 40(2), 97-107.





Panels – One Size Doesn't Fit All

Panel 1		Panel 3	
Marijuana	Demol 0	Marijuana	
Cocaine	Panel 2	Cocaine	
Opiates	Marijuana	Opiates	
Oxycodone	Cocaine	Phencyclidine	
Phencyclidine	Opiates	Amphetamines	. 000
Amphetamines	Ethanol	MDMA (Ecstasy)	
MDMA (Ecstasy)	Phencyclidine	Barbiturates	
Barbiturates	Amphetamines	Benzodiazepines	
Benzodiazepines	Barbiturates	Methadone	
Methadone	Benzodiazepines	Propoxyphene	
Propoxyphene			



www.afforditNOW.com

The Expanded Screen Something is (always) Missing

Drugs/Drug Classes
Amphetamines
Barbiturates
Benzodiazepines
Buprenorphine
Carisoprodol
Cocaine
Ethyl Glucuronide
Fentanyl
MDMA (Ecstasy)
Meperidine
Methadone
Opiates
Oxycodone
Phencyclidine
Propoxyphene
Tapentadol
Tramadol
THC (Cannabinoids)
Zolpidem




www.iwebstreet.com






Mass Spec-based Screen







MS: Quadrupoles and Flight Tubes







Benefits of a MS Screen

- Sensitivity & Specificity on par with classic "confirmatory" methods
- Individual compound/metabolite identification
- Elimination of cross-reactivity complications
- Drug/metabolite pairs for interpretations
- Drug abuse testing conducted concurrently for high risk populations
- Relatively easy integration of new targets
- If qualitative "Reflex to Quantitation" still possible when needed




Pain Med, 2018 Jul 17. pii: pnw185. [Epub ahead of print] Cost and Efficacy Assessment of an Alternative Medication Compliance Urine Drug Testing Strategy. Doyle K¹, Strathmann FG². Author information






Panels – One Size Doesn't Fit All







One Size Fits All. Not the Right Answer.







What are we looking for from a workflow?

- Qualitative screen to rule out
 - Allows broad panel
 - Detect illicit drugs
 - Detect abuse
 - Sensitive/Specific
 - Cheap
 - Fast

ABORATORIES

- Comprehensive
- Easy (for the lab!)


- Quantitative confirmation
 - Sensitive/Specific
 - Metabolite ratios
 - Pharmaceutical impurities
 - D/L Ratios



www.mogicons.com



One Exciting New Possibility *LC-TOF Rapid Screen*




- < 1.2 minutes to cover ALL currently offered immunoassays
- Cost equivocal to a routine 9 compound immunoassay panel
- Includes enzymatic hydrolysis for added sensitivity






Analytical Performance







Quantitative Creatinine Result Included




- Imprecision
 - 3% @ 87 mg/dL
 - 2% @ 230 mg/dL
- Accuracy
 - 8% bias throughout AMR (20-400 mg/dL)



LABORATORIES

Custom Panels with Confirmation







Summary & Key Points

- MKAE THE CMLOPEX SIMPLE
- Design Testing with the Patient and Physician in Mind, not Reimbursement.
- Find the Right Technology for the Right Job.
- The Future is in Intelligently Designed Custom Panels Using Advanced Screening Capabilities with Tried and True Confirmatory Methods.







Contact Information

Frederick G. Strathmann, PhD, DABCC (CC, TC)

ARUP Laboratories

Assistant Professor

Department of Pathology, University of Utah

frederick.g.strathmann@aruplab.com





ABORATORIES